Bisphosphonate use and gastrointestinal tract cancer risk: Meta-analysis of observational studies

doi:10.3748/wjg.v18.i40.5779

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 40

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5177)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

413

HTML

4247

Figures (1-2)

275

Tables (1-4)

242

Sum=5177

Oct 28, 2012 (publication date) through Jan 4, 2025

Times Cited of This Article

Times Cited (24)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Oct 28, 2012; 18(40): 5779-5788
Published online Oct 28, 2012. doi: 10.3748/wjg.v18.i40.5779

Table 2 Characteristics of cohort studies (n = 3) included in meta-analysis regarding use of bisphosphonates and risk of cancer

Ref.	Country	Cohort formation (population)	Study period	Mean F/U duration, yr (range)	Age, yr (mean±SD)	Sex ratio (reference group)	Type of cancer	Type of drug (reference group)	Risk estimate	Adjustment	No. of cancer development/ no. of study population		No. of total cohort
											Bisphosphonate user	Reference group
Abrahamsen et al[10]	Denmark	Patients with fracture who had prescription for oral bisphosphonate (national registers)	E:1995-2005; F/U: -2005	2.8 (NA)	74.3 ± 8.8	M: 11; F: 89	Esophageal cancer, gastric cancer	Any bisphosphonate use (no bisphosphonate use)	Esophageal or gastric cancer 0.78 (0.49-1.26); esophageal cancer 0.35 (0.14-0.85); gastric cancer 1.23 (0.68-2.22)	Age, sex, fracture type, Charlson index, number of concomitant medication, time to event	NA/13 678	NA/27 356	41 034
Solomon et al[11]	United States	Patients who had prescription for oral bisphosphonate (health care utilization records of medicare beneficiaries)	NA	NA (NA)	NA	NA	Esophageal cancer	Any bisphosphonate use (other osteoporosis medications use)	Esophageal cancer 0.55 (0.06-4.72)	NA	Incidence rate 26.7/100 000	Incidence rate 48.4/100 000	NA
Cardwell et al[7]	United Kingdom	Patients receiving prescription for oral bisphosphonate (GPRD)	E:1996-2006; F/U: -2008	4.5 (0.5-12.9)	70.0 ± 11.4	M: 19; F: 81	Esophageal cancer, gastric cancer	Any bisphosphonate use (regardless of bisphosphonate use)	Gastric cancer 0.78 (0.50-1.23); esophageal cancer 1.07 (0.77-1.49)	Age, sex, general practice, BMI, cigarette smoking, alcohol intake, hormone therapy, NSAID use, Barrett's esophagus, GERD, H2 receptor antagonist use, proton pump inhibitor use	Esophageal or gastric cancer 116/41 826 (gastric cancer 37/41 826; esophageal cancer 79/41 826)	Esophageal or gastric cancer 115/41 826 (gastric cancer43/41 826; esophageal cancer 72/41 826)	83 652

E: Enrollment; F/U: Follow up; BMI: Body mass index; GERD: Gastroesophageal reflux disease; NSAID: Nonsteroidal antiinflammatory drugs; M: Male; F: Female; NA: Not available; GPRD: General Practice Research Database.

Citation: Oh YH, Yoon C, Park SM. Bisphosphonate use and gastrointestinal tract cancer risk: Meta-analysis of observational studies. World J Gastroenterol 2012; 18(40): 5779-5788
URL: https://www.wjgnet.com/1007-9327/full/v18/i40/5779.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i40.5779